Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Cell Culture Flasks

November 7, 2011 12:08 pm | Product Releases | Comments

Cell culture flasks combine high-pressure molded 100% USP Class VI virgin crystal polystyrene with a low-pressure gas plasma surface treatment.

Barcoded Tubes

November 7, 2011 12:07 pm | Product Releases | Comments

Thermo Fisher Scientific Inc.’s Matrix Amber 2D barcoded tubes are available in 0.5 and 1.0 mL sizes.

Roche Gains Head of Oncology Discovery

November 7, 2011 12:05 pm | News | Comments

Pamela Carroll, PhD, has joined Roche as head of the Nutley Oncology Discovery Site and Global Pathways Biology within Pharma Research and Early Development.

TOPICS:
Advertisement

Frederick Manufacturing Center is ISPE Facility of the Year

November 7, 2011 12:01 pm | News | Comments

MedImmune’s Frederick Manufacturing Center Expansion Facility is the winner of the 2011 Facility of the Year Awards program.

TOPICS:

Aslan, BMS Partner for Oncology Compound

November 7, 2011 11:58 am | News | Comments

Aslan Pharmaceuticals and Bristol-Myers Squibb Co. have partnered to develop BMS-777607, BMS’ investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.

TOPICS:

Ancor Acquires WellSpring Pharmaceuticals

November 7, 2011 11:55 am | News | Comments

Ancor Capital Partners acquired WellSpring Pharmaceuticals, a manufacturer and marketer of specialty prescription and over-the-counter products in North America, as well as contract manufacturing services.

TOPICS:

Researchers Devise Key Taxol Production Step

November 7, 2011 11:51 am | News | Comments

Finding an efficient way to produce Taxol, a highly successful drug used to treat ovarian, breast, lung, liver, and other cancer types, in the laboratory remains one of the most sought-after goals in organic chemistry.

Final Results Released for Hepatitis C Drug

November 7, 2011 11:48 am | News | Comments

Tibotec Pharmaceuticals announced the final analysis of Pillar, a Phase 2b study of the investigational hepatitis C virus NS3/4A protease inhibitor TMC435 in patients with chronic genotype 1 HCV.

Advertisement

Genes Discovered In Colorectal Cancer

November 7, 2011 11:35 am | News | Comments

A jumping gene with the fairy tale name 'Sleeping Beauty' has helped to unlock vital clues for researchers investigating the genetics of colorectal cancer.

Compliance Software

November 7, 2011 7:17 am | Product Releases | Comments

PerkinElmer, Inc. introduced the NexION Enhanced Security Software, to streamline regulatory compliance by pharmaceutical companies. The ES Software platform was developed for users of PerkinElmer's NexION 300 ICP-MS system.

TOPICS:

Dishwasher Thermometer

November 7, 2011 7:14 am | Product Releases | Comments

Control Company’s Traceable dishwasher metal thermometer reports the maximum and minimum temperatures insures proper cleaning by providing proof of meeting the temperature regulation of 180°F during dishwashing.

TOPICS:

Horizon Discovery Partnering with Promega

November 7, 2011 6:53 am | News | Comments

Horizon Discovery Ltd. announced a partnership with Promega Corporation centering on the delivery of endogenous gene reporting capabilities, in the form of Promega’s luciferase and HaloTag reporters, using Horizon’s genome editing technology.

TOPICS:

Ardea Biosciences Reports $22M Loss

November 7, 2011 6:28 am | News | Comments

Ardea Biosciences Inc. reported a larger third-quarter loss as it continued to develop its gout drug candidates and its revenue decreased. Ardea said its net loss amounted to $22.5 million, or 84 cents per share, for the three months ended Sept. 30.

TOPICS:

NicVAX Falls Flat in Late-Stage Trial

November 7, 2011 6:24 am | News | Comments

Nabi Biopharmaceuticals announced that NicVAX did not meet its primary endpoint in the second of two confirmatory Phase 3 clinical trials. An assessment of the trial data showed that no statistical difference between the NicVAX and placebo groups.

TOPICS:

FDA Clears Xarelto for Atrial Fibrillation

November 7, 2011 6:14 am | News | Comments

More than 2 million new U.S. patients will be eligible to receive a next-generation blood thinner drug called Xarelto, after the Food and Drug Administration approved the medication to treat a common heart problem that can lead to stroke.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading